S866 PHASE 1/2 TRIAL OF ACALABRUTINIB PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Authors :: Julie M. Vose
Kathryn S. Kolibaba
Priti Patel
Roger M. Lyons
Kami J. Maddocks
Helen Wei
Jennifer E. Vaughn
Jeffrey P. Sharman
Mitul Gandhi
T. E. Witzig
William Jeffery Edenfield
Habte A. Yimer
Felipe Samaniego
C. Di Simone
Bruce D. Cheson
Edward M. Chan
S. de Vos
Source :: HemaSphere. 3:387-388
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: medicine.medical_specialty
business.industry
Internal medicine
Relapsed refractory
medicine
Acalabrutinib
In patient
Hematology
Pembrolizumab
business
medicine.disease
Gastroenterology
Diffuse large B-cell lymphoma

Tools